Barclays’s AMAG Pharmaceuticals AMAG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-2,000
| Closed | -$19K | – | 5279 |
|
|
2020
Q3 | $19K | Hold |
2,000
| – | – | ﹤0.01% | 4906 |
|
|
2020
Q2 | $15K | Sell |
2,000
-7,700
| -79% | -$58.9K | ﹤0.01% | 5269 |
|
|
2020
Q1 | $60K | Buy |
9,700
+7,400
| +322% | +$65.2K | ﹤0.01% | 5118 |
|
|
2019
Q4 | $28K | Sell |
2,300
-3,000
| -57% | -$32.8K | ﹤0.01% | 5910 |
|
|
2019
Q3 | $61K | Sell |
5,300
-12,600
| -70% | -$133K | ﹤0.01% | 5805 |
|
|
2019
Q2 | $179K | Buy |
17,900
+6,100
| +52% | +$65.8K | ﹤0.01% | 5216 |
|
|
2019
Q1 | $152K | Sell |
11,800
-18,100
| -61% | -$270K | ﹤0.01% | 5042 |
|
|
2018
Q4 | $454K | Buy |
29,900
+22,100
| +283% | +$421K | ﹤0.01% | 3900 |
|
|
2018
Q3 | $156K | Sell |
7,800
-2,700
| -26% | -$61.5K | ﹤0.01% | 5195 |
|
|
2018
Q2 | $205K | Sell |
10,500
-18,200
| -63% | -$403K | ﹤0.01% | 4704 |
|
|
2018
Q1 | $578K | Buy |
28,700
+4,400
| +18% | +$74.4K | ﹤0.01% | 3830 |
|
|
2017
Q4 | $322K | Sell |
24,300
-33,000
| -58% | -$498K | ﹤0.01% | 4274 |
|
|
2017
Q3 | $1.06M | Buy |
57,300
+41,500
| +263% | +$773K | ﹤0.01% | 2943 |
|
|
2017
Q2 | $291K | Buy |
15,800
+14,800
| +1,480% | +$293K | ﹤0.01% | 4043 |
|
|
2017
Q1 | $23K | Buy |
1,000
+800
| +400% | +$19.2K | ﹤0.01% | 5751 |
|
|
2016
Q4 | $7K | Sell |
200
-4,600
| -96% | -$137K | ﹤0.01% | 6049 |
|
|
2016
Q3 | $118K | Sell |
4,800
-6,400
| -57% | -$160K | ﹤0.01% | 4398 |
|
|
2016
Q2 | $268K | Buy |
11,200
+7,900
| +239% | +$181K | ﹤0.01% | 3706 |
|
|
2016
Q1 | $76K | Buy |
3,300
+2,200
| +200% | +$52.2K | ﹤0.01% | 4539 |
|
|
2015
Q4 | $33K | Sell |
1,100
-1,300
| -54% | -$42K | ﹤0.01% | 5000 |
|
|
2015
Q3 | $94K | Sell |
2,400
-3,600
| -60% | -$223K | ﹤0.01% | 4659 |
|
|
2015
Q2 | $414K | Sell |
6,000
-5,100
| -46% | -$321K | ﹤0.01% | 3623 |
|
|
2015
Q1 | $599K | Buy |
11,100
+4,400
| +66% | +$210K | ﹤0.01% | 3427 |
|
|
2014
Q4 | $281K | Buy |
6,700
+6,000
| +857% | +$217K | ﹤0.01% | 4367 |
|
|
2014
Q3 | $22K | Sell |
700
-300
| -30% | -$6.4K | ﹤0.01% | 6432 |
|
|
2014
Q2 | $20K | Sell |
1,000
-200
| -17% | -$3.7K | ﹤0.01% | 6516 |
|
|
2014
Q1 | $23K | Buy |
+1,200
| New | +$25.5K | ﹤0.01% | 6541 |
|
|
2013
Q4 | – | Sell |
-400
| Closed | -$8K | – | 7758 |
|
|
2013
Q3 | $8K | Sell |
400
-2,100
| -84% | -$49.6K | ﹤0.01% | 6865 |
|
|
2013
Q2 | $56K | Buy |
+2,500
| New | +$55.1K | ﹤0.01% | 6237 |
|
Barclays's AMAG Position: Q4 2020 in Review
Barclays sold out of AMAG Pharmaceuticals (AMAG) in Q4 2020, closing a stake of 38,001 shares — an estimated $357K sold.
Barclays first reported a position in AMAG in Q2 2013 and held it in 30 quarters. The position peaked at $2.65M in Q3 2014. 1 fund tracked by Wall St. Rank holds AMAG as of Q4 2020.
- Barclays reported no remaining AMAG Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
- Barclays sold 38,001 AMAG Pharmaceuticals shares in Q4 2020, an estimated $357K.
- Barclays first reported a position in AMAG Pharmaceuticals in Q2 2013 and held it in 30 quarters.
- Barclays's AMAG Pharmaceuticals position peaked at $2.65M in Q3 2014.
- 1 fund tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2020.
Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.